vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program TranscriptSeeking Alpha · 4 days ago
vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 HypoglycemiaMarketBeat · 4 days ago
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseGlobeNewsWire · Oct 7, 2026
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026GlobeNewsWire · Oct 6, 2026
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)Defense World · Oct 5, 2026
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)GlobeNewsWire · Oct 5, 2026vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.97 | -$1.05 | Miss |
| May 13, 2026 | $0.34 | $1.65 | Beat |
| Mar 10, 2026 | -$0.98 | -$0.58 | Beat |
| Nov 6, 2025 | -$0.97 | -$1.08 | Miss |
| Aug 12, 2025 | -$0.85 | -$0.92 | Miss |
| May 15, 2025 | -$0.73 | -$0.77 | Miss |